Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-58

@col69

Mesoblast is making good progress with Ryoncil . The first month’s patient numbers are in line or better than Bell Potters forecasts, as is net operating cash burn. The shorters will be very active trying to stop the price breaking out today …but it is just a matter of time now, before, in my opinion, they lose control. Latest reported two week figures from Nasdaq show short sales for the US listing alone have been increasing at an average value of over US$300k per trading day to hold the price down , but this rate of shorting is not really sustainable for much longer, because i believe the borrow will dry up and the fee rate will rise to an unacceptable level.. as it has done in the past at similar lending percentages.

GVHD is doing fine. The blockbuster indications of back and heart are about to move to centre stage. I think the market is asleep.

Expect a breakout is my conclusion. These numbers are good enough to merit a short squeeze in the next two months. The Type B meeting for heart might be the trigger for a re rating. OP


Please do not rely on the facts or opinions expressed in the above post when making an investment decision.